EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study

Ähnliche Einträge

• Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
  von: Schütte, Wolfgang, et al.
  Veröffentlicht: (2018)
• First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
  von: Carbone, David P., et al.
  Veröffentlicht: (2017)
• Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR- expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE)
  von: Reck, Martin, et al.
  Veröffentlicht: (2016)
• Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer
  von: Schiller, Joan H., et al.
  Veröffentlicht: (2010)
• Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
  von: Saalfeld, Felix, et al.
  Veröffentlicht: (2024)